News | September 27, 2024
Zydus and CSIR-CDRI Lucknow to develop drug for CKD induced Osteoporosis
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Subscribe To Our Newsletter & Stay Updated
